FamciclovirAPO-FAMCICLOVIR

Cost-minimisation analysis for suppressive therapy against aciclovir; cost-effectiveness analysis for episodic treatment with incremental cost per additional patient avoiding new HSV lesions <$1,000 and per patient avoiding HSV shedding or lesions/symptoms <$15,000. No modelled economic evaluation presented.

The PBAC recommended the listing of famciclovir for suppressive therapy of moderate to severe recurrent oral or labial herpes in patients with HIV infection with CD4 cell counts of less than 150 per microliter or other opportunistic infections or AIDS defining tumours, on a cost-minimisation basis against aciclovir at the price proposed in the submission. PBAC · 2006

PopulationPatients with HIV infection and CD4 cell counts less than 500 per microlitre (episodic treatment) or less than 150 per microlitre or with other opportunistic infections or AIDS-defining tumours (suppressive therapy) with moderate to severe recurrent orolabial herpes.